• Home Suggests clinical trial results published in todays online edition of The Lancet.

Suggests clinical trial results published in todays online edition of The Lancet.

Both products are produced by Advanced Circulatory Systems, Inc. in Roseville, Minn. Dr. Tom P. Aufderheide, Professor of Emergency Medicine at the Medical University of Wisconsin in Milwaukee was initially author and a principal investigator at one of the study sites. ‘The goal of resuscitation during cardiac arrest is normally long-term survival with preservation of mind function,’ commented Dr. Aufderheide. ‘This brand-new, effective intervention achieves that goal and is potentially the most important advancement in the treatment of cardiac arrest since defibrillation.’ Ralph J.Importantly, these studies allowed us to unequivocally demonstrate the sequence-specific character of the protection afforded by our drug candidates. AVI offers received a ‘safe to proceed’ allowance from the United States Food and Drug Administration for IND applications for clinical basic safety trials of its two business lead products to take care of Ebola and Marburg virus infections. These INDs signify the first TMTI supported drug candidates targeting bioterrorism brokers to get FDA IND allowance. Related StoriesUC Irvine Health experts develop one-step check to detect HCV infectionsStudy provides novel insight into the development of hepatitis A virus and how it spreads to humansBlocking calcium-signaling pathway could inhibit Ebola virus and other resources of deadly infectionsAVI plans to conduct the pet efficacy trials for potential acceptance of its drugs under the Animal Rule as part of its continued collaboration with USAMRIID.